Fungal infections represent a growing global health threat, driven by their increasing incidence, high mortality rates, and limited therapeutic options. They disproportionately affect at-risk populations such as immunocompromised individuals, transplant recipients, and patients undergoing intensive medical treatments. The situation is further exacerbated by challenges in early diagnosis, delayed treatment, and the rise of antifungal resistance. Additionally, climate change has emerged as a contributing factor, expanding the geographic range and virulence of pathogenic fungi, thereby intensifying the global burden of these infections. Supporting these concerns, recent estimates indicate a global annual incidence of approximately 6.5 million cases of invasive fungal infections -recognized as the most severe and treatment-resistant forms of mycoses -which are responsible for nearly 3.8 million deaths worldwide each year (Vitiello et al. 2023;Denning 2024). Despite the pressing demand for effective antifungal treatments, current therapeutic options are hampered by several significant challenges. These include a restricted variety of drug classes, increasing rates of resistance, concerns regarding toxicity, suboptimal pharmacokinetics, and complicated drug-drug interactions. These factors collectively hinder the development and effectiveness of antifungal therapies, necessitating innovative solutions and more comprehensive strategies to improve patient outcomes (Meis et al. 2016;Corrêa-Junior et al. 2025). In response to these challenges, there is a pressing necessity to uncover efficient and novel antifungal agents and/or repurposing of existing drugs introducing new mechanisms of action and avoid cross-resistance with current treatments. Additionally, optimizing combination therapies to mitigate resistance development has been identified as a strategic priority (Mota Fernandes et al. 2021). Of particular concern is Candida albicans, Candida auris, Cryptococcus neoformans and Aspergillus fumigatus, which were designated World Health Organization (WHO) critical priority fungal pathogen list (FPPL) in 2022 (WHO 2022). In alignment with this global call to action, the researchers are advancing the development of novel antimicrobial agents with promising antifungal properties aims to (i) enhance the antifungal efficacy, (ii) evaluate the activity against drug-resistant fungal species, and (iii) investigate synergistic combinations with existing antifungal agents to reduce the emergence of resistance. The editors Maryam Roudbary, Marta Branquinha and André Santos proposed the publication of this special issue, titled "Drug Repurposing to Fight Resistant Fungal Species: Recent Developments as Novel Therapeutic Strategies", in Frontiers in Cellular and Infection Microbiology. This initiative aims to advance the ongoing legacy of research in Medical Mycology while fostering the discovery and development of innovative therapeutic strategies to overcome drug resistance posing a therapeutic failure in healthcare system. This special issue serves as a dedicated platform for the dissemination of cutting-edge research, critical analyses, and emerging perspectives on the urgent challenge of antifungal resistance. It features a carefully curated collection of nine contributions, comprising six original research articles, one comprehensive review, one opinion piece, and one corrigendum. Collectively, these works reflect the depth of current progress in the field. To provide readers with a clear and engaging overview, concise summaries of each article are presented below. The first paper, authored by Hu et al. (2024), describes two cases of Pythium insidiosum infection -one ocular and one cutaneous -diagnosed through metagenomic nextgeneration sequencing (mNGS). Zoospore induction enabled successful drug susceptibility testing, revealing that conventional antifungals and common antimicrobials were ineffective. However, significant in vitro activity was observed with minocycline, tigecycline, linezolid, erythromycin, and azithromycin. Guided by these findings and supported by zoospore-based susceptibility profiling, a tailored therapeutic approach was implemented, leading to marked clinical improvement and eventual recovery in the cutaneous case. The study highlights the importance of early diagnosis, appropriate antimicrobial selection and surgical intervention in managing pythiosis. The study by Itoh et al. (2024) demonstrates that minocycline, when combined with caspofungin, exerts a synergistic antifungal effect, representing a promising therapeutic strategy against Candida infections, including drug-resistant strains, and surpassing rapamycin as a clinical candidate. This combination operates through a dual mechanism: it potentiates antifungal activity by simultaneously disrupting fungal cell wall integrity and inhibiting protein synthesis, while also modulating host immune responses by suppressing key signaling pathways -most notably through TOR (Target of Rapamycin) inhibition by minocycline. These findings underscore the enhanced clinical potential of minocyclinecaspofungin co-therapy as an effective and multifaceted approach to combat Candida infections.In the published study by König et al. (2024) highlights the dual antifungal and antiviral potential of ProcCluster® and procaine hydrochloride, which are prodrugs derived from the local anesthetic procaine, against Aspergillus species and influenza A virus. Both compounds inhibited fungal growth, including triazole-resistant A. fumigatus, and reduced viral replication in lung epithelial coinfection models. ProcCluster® disrupted fungal calcium homeostasis, a mechanism reversed by addition of calcium chloride. Interestingly, combination the antiviral favipiravir and ProcCluster® showed enhanced activity against influenza A virus. These findings suggest promising broad-spectrum activity for these compounds in managing...